Vidarbha News

The Dynamics of the Alzheimer’s Disease Market are expected to transform positively in the upcoming years owing to an increase in global healthcare spending, better understanding and influx of key com

 Breaking News
  • No posts were found

The Dynamics of the Alzheimer’s Disease Market are expected to transform positively in the upcoming years owing to an increase in global healthcare spending, better understanding and influx of key com

May 21
01:21 2021
The Dynamics of the Alzheimer's Disease Market are expected to transform positively in the upcoming years owing to an increase in global healthcare spending, better understanding and influx of key com

Alzheimer’s Disease Market
Alzheimer’s Disease Market Insights Report by DelveInsight provides information on existing clinical strategies, new drugs, available therapies, epidemiology, Alzheimer’s Disease market share of individual therapies, and current and forecasted Alzheimer’s Disease market size from 2018 to 2030, segmented into 7MM (the United States, EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Alzheimer’s Disease Market Insights Report by DelveInsight provides information on existing clinical strategies, new drugs, available therapies, epidemiology,  Alzheimer’s Disease market share of individual therapies, and current and forecasted Alzheimer’s Disease market size from 2018 to 2030, segmented into 7MM (the United States, EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Some of the Key Highlights from the Alzheimer’s Disease Market Report

  • Around 6 million Americans had Alzheimer’s Disease in 2020, and it was discovered that younger people can get Alzheimer’s disease, although it is less common.

  • Nearly half of Alzheimer’s Disease patients have a mild to serious form of disease (Yuan et al. 2021). 50.4 percent of people with Alzheimer’s Disease had mild symptoms, 30.3 percent had moderate symptoms, and 19.3 percent had extreme symptoms.

  • Women are disproportionately affected by Alzheimer’s Disease, according to the Alzheimer’s Association (2021). Alzheimer’s Disease and other dementias affect more women than men. Women account for almost two-thirds of Alzheimer’s patients in the United States.

  • Pipeline therapies for Alzheimer’s Disease includes Lecanemab (BAN2401) (Eisai/BioArctic AB), Aducanumab (BIIB037) (Biogen), Gantenerumab (Hoffmann-La Roche), Tricaprilin (Cerecin), Brexpiprazole (Otsuka Pharmaceutical), Brilaroxazine (RP5063) (Reviva Pharmaceutical), ALZT-OP1 (AZ Therapies), and others.

  • Eisai/BioArctic AB, Biogen, Hoffmann-La Roche, Cerecin, Otsuka Pharmaceutical, Reviva Pharmaceutical, AZ Therapies, are some of the major companies that are involved in the Alzheimer’s Disease market.

To gain more knowledge request sample @ Alzheimer’s Disease Market Insights

The Alzheimer’s Disease market report covers new clinical practises, emerging drugs, individual therapy market shares, and current and forecasted Alzheimer’s Disease market sizes from 2018 to 2030, segmented into seven major markets. To curate the best of the opportunities and evaluate the market’s underlying potential, the report also addresses existing Alzheimer’s Disease management practice/algorithm, market dynamics, market challenges, and unmet patient needs.

Alzheimer’s Diseases: Overview

Alzheimer’s Disease is a chronic neurological condition that progressively erodes memory and cognitive skills, as well as the ability to perform even basic tasks. Simple activities such as driving a car, cooking a meal, or paying bills are difficult for Alzheimer’s patients. They are prone to asking the same questions over and over, being easily disoriented, dropping or misplacing items, and finding even basic things perplexing. As the disease progresses, some people become worried, irritated, or aggressive.

Alzheimer’s Disease Epidemiology Segmentation

  • Alzheimer’s Disease Total Prevalent Cases

  • Alzheimer’s Disease Total Diagnosed Prevalent Cases

  • Alzheimer’s Disease Total Age-Specific Diagnosed Prevalent Cases

  • Alzheimer’s Disease Total Gender-Specific Diagnosed Prevalent Cases

  • Alzheimer’s Disease Total Severity-Specific Diagnosed Prevalent Cases

  • Alzheimer’s Disease Total Treated Cases

Alzheimer’s Disease Treatment Landscape

There is no known cure for Alzheimer’s Disease, but current treatments aim to help people retain mental function, control behavioural symptoms, and delay the progression of some issues like memory loss. Cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda) are two types of medications licenced by the US FDA for the treatment of Alzheimer’s Disease.

Alzheimer’s Disease Market

Key pharmaceutical companies such as Eisai/BioArctic AB, Biogen, Hoffmann-La Roche, Cerecin, Otsuka Pharmaceutical, Reviva Pharmaceutical, AZ Therapies, and others are expected to introduce new therapies in the Alzheimer’s Disease Market.

The introduction of Lecanemab (BAN2401) (Eisai/BioArctic AB), Aducanumab (BIIB037) (Biogen), Gantenerumab (Hoffmann-La Roche), Tricaprilin (Cerecin), Brexpiprazole (Otsuka Pharmaceutical), Brilaroxazine (RP5063) (Reviva Pharmaceutical), ALZT-OP1 (AZ Therapies), and others is expected to give the Alzheimer’s Disease market a significant boost in the forecast period 2021-30 in the 7MM.

In addition, extensive R&D in the domain, as well as rising Alzheimer’s Disease prevalence, are propelling the Alzheimer’s Disease market size forward.

For more insights into market visit Alzheimer’s Disease Market Scenario

Alzheimer’s Disease Pipeline Therapies and Major Players

  • Lecanemab (BAN2401): Eisai/BioArctic AB

  • Aducanumab (BIIB037): Biogen

  • Gantenerumab: Hoffmann-La Roche

  • Tricaprilin: Cerecin

  • Brexpiprazole: Otsuka Pharmaceutical

  • Brilaroxazine (RP5063): Reviva Pharmaceutical

  • ALZT-OP1: AZ Therapies

Alzheimer’s Disease Market Drivers

  • At present, no disease modifying drug is available for AD, which creates a significant market opportunity for Pharmaceutical companies. Development of disease modifying treatment for AD, can shift the market dynamics significantly

  • A growing elderly population, and increasing prevalence

Alzheimer’s Disease Market Barriers

  • Barriers to Early Diagnosis and Treatment

  • Lack of disease modifying drugs

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)

Study Period: 2018-30

Alzheimer’s Disease Key Companies: Eisai/BioArctic AB, Biogen, Hoffmann-La Roche, Cerecin, Otsuka Pharmaceutical, Reviva Pharmaceutical, AZ Therapies, among others. 

Alzheimer’s Disease Key Pipeline Therapies: Lecanemab (BAN2401) (Eisai/BioArctic AB), Aducanumab (BIIB037) (Biogen), Gantenerumab (Hoffmann-La Roche), Tricaprilin (Cerecin), Brexpiprazole (Otsuka Pharmaceutical), Brilaroxazine (RP5063) (Reviva Pharmaceutical), ALZT-OP1 (AZ Therapies), and others.

Alzheimer’s Disease Market Segmentation: By Geography, By Alzheimer’s Disease therapies

Analysis: Comparative and conjoint analysis of Alzheimer’s Disease emerging therapies

Tools Used: SWOT Analysis

Case Studies

KOL’s Views

Analyst’s Views

Table of Contents

1.

Report Introduction

2.

Executive Summary of Alzheimer’s Disease

3.

SWOT Analysis of Alzheimer’s Disease

4.

Alzheimer’s disease: Patient Share (%) Overview at a Glance

5.

Alzheimer’s Disease : Market Overview (%) at a Glance

6.

Alzheimer’s Disease: Disease Background and Overview

7.

Alzheimer’s Disease: Epidemiology and Patient Population

8.

Country-Specific Patient Population of Alzheimer’s Disease

9.

Alzheimer’s Disease: Current Treatment and Medical Practices

10.

Alzheimer’s Disease: Patient Journey

11.

Alzheimer’s Disease: Unmet Needs

12.

Alzheimer’s Disease: Key Endpoint of Clinical Trials

13.

Alzheimer’s Disease: Marketed Products

14.

Alzheimer’s Disease: Emerging Therapies

15.

Conjoint Analysis of Alzheimer’s Disease  Therapies

16.

Alzheimer’s Disease : Market Size of 7MM

17.

Alzheimer’s Disease: Country-Wise Market Analysis (2018–2030)

18.

Market Access and Reimbursement of Alzheimer’s Disease  therapies

19.

Alzheimer’s Disease Market drivers

20.

Alzheimer’s Disease Market barriers

21.

Appendix

22.

DelveInsight Capabilities

23.

Disclaimer

24.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Related Reports

AL Amyloidosis Market

Get comprehensive historical and forecast analysis of AL Amyloidosis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Janssen Pharmaceutical, Caelum Biosciences, Oncopeptides AB, Bristol-Myers Squibb, Acrotech biopharma, Sanofi, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/